Comparison of the Effectiveness Metformin for Deceasing Proliferative Marker in Endometrial Cancer Cells

Completed 50 enrolled Department of Medical Services Ministry of Public Health of Thailand

RandomizedParallel-groupDouble-blindTreatment

Summary

Comparison of the effectiveness metformin versus placebo for deceasing proliferative marker Ki-67 expression in endometrial tumours when given for 4 weeks before hysterectomy in endometrial cancer cells.

Timeline

Start: 2018-07-01
Primary completion: 2019-11-30
Completion: 2020-01-30

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Metformin	Small molecule	850 mg	Oral

Comparison of the Effectiveness Metformin for Deceasing Proliferative Marker in Endometrial Cancer Cells

Summary

Timeline

Drugs

Indications